{"schema_version":"secwatch.filing_event.v1","accession":"0000784199-21-000203","form_type":"8-K","ticker":"AORT","cik":"0000784199","company_name":"ARTIVION, INC.","filed_at":"2021-11-04T23:59:59+00:00","discovered_at":"2026-05-14T18:04:15.581484+00:00","generated_at":"2026-06-28T13:29:26.311666+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"CryoLife Q3 revenue $72.2M (+11% YoY); net income $10.6M; non-GAAP EPS ($0.03)","bullets":["Revenue $72.2M, up 11% GAAP and 9% constant currency vs Q3 2020.","GAAP net income $10.6M ($0.26 EPS) vs net loss ($2.9M) year ago.","Non-GAAP net loss ($1.2M) ($0.03 EPS) vs prior non-GAAP net income $4.9M ($0.13).","2021 outlook: full-year revenue $296-299M; Q4 $76.5-79.5M, pro forma constant currency growth 9.5-13.7% vs Q4 2019.","Submitted PMAs to FDA for PerClot and PROACT Mitral; approvals expected in 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0000784199-21-000203","json":"https://secwatch.observer/filing/0000784199-21-000203.json","markdown":"https://secwatch.observer/filing/0000784199-21-000203.md","text":"https://secwatch.observer/filing/0000784199-21-000203.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/784199/000078419921000203/0000784199-21-000203-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/784199/000078419921000203/cry-20211104x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T13:29:26.311666+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}